Sangamo Therapeutics, Inc. (SGMO)

0,6360 +0,0386 (+6,46%) Al cierre: 04:00PM EDT

Sangamo Therapeutics, Inc.

501 Canal Blvd
Richmond, CA 94804
United States
510-970-6000
https://www.sangamo.com

Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 405

Ejecutivos clave

Nombre	Título	Paga	Ejecutado	Año de nacimiento
Dr. Alexander D. Macrae Ch.B, M.B., MRCP, Ph.D.	CEO, President & Director	722,67k	N/A	1963
Ms. Prathyusha Duraibabu CPA, M.B.A.	Senior VP, CFO & Principal Accounting Officer	490,26k	N/A	1979
Dr. Nathalie Dubois-Stringfellow Ph.D.	Senior VP & Chief Development Officer	459,9k	N/A	1962
Ms. Amy Pooler Ph.D.	Head of Research	N/A	N/A	N/A
Mr. Gregory Davis Ph.D.	Head of Technology	N/A	N/A	N/A
Ms. Aron Feingold	Head of Corporate Communications & Investor Relations Officer	N/A	N/A	N/A
Mr. Scott B. Willoughby	Senior VP, General Counsel & Corporate Secretary	N/A	N/A	1975
Phillip Ramsey	Head of Technical Operations	N/A	N/A	N/A
Ms. Stephanie J. Seiler CLP	Head of Business Development & Alliance Management	N/A	N/A	N/A
Mr. David Ojala	Scientist II - Discovery & Translational Research	N/A	N/A	N/A

Los importes son a partir de 31 de diciembre de 2023 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease. Its preclinical development products focus on CAR-Treg cell therapies for autoimmune disorders and genome engineering for neurological diseases. Sangamo Therapeutics, Inc. has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Richmond, California.

Gobierno corporativo

El ISS Governance QualityScore de Sangamo Therapeutics, Inc., a día 1 de mayo de 2024, es 3. Las puntuaciones base son Auditoría: 6; Tablero: 1; Derechos de los accionistas: 2; Compensación: 6.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.